Moteur de recherche d’entreprises européennes
Financement de l’UE (3 969 936 €) : CHANGEMENTS LIÉS À L’ÂGE DANS L’HÉMATOPOÏÈSE Hor01/06/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
CHANGEMENTS LIÉS À L’ÂGE DANS L’HÉMATOPOÏÈSE
ARCH is a network of highly qualified experts in experimental hematology created to decipher the causal relationship between the physiological changes in the hematopoietic system during lifespan and the parallel occurrence of specific age-related hematological diseases (pediatric, adult, elderly), with the aim to develop novel targeted therapeutic treatments. ARCH research will integrate the results from complementary model systems (cell lines, mouse models, cells from leukemia patients) and it will deploy a large panel of cutting-edge technologies, such as single cells genomics, epigenomics, genome editing and organoid cultures, in a multi-faceted effort. The ARCH ambitious goal requires scientific and financial resources beyond the capability of a single group. To reach this goal, the ARCH network brings together 15 beneficiaries (12 academic, 2 SMEs and 1 private research institute) and 5 Partner organisations (3 academic, 1 SME and 1 patients’ association). Two European Consortia are present through their italian nodes. ARCH will recruit 15 ESRs that will be all enrolled in PhD programmes. Besides research laboratory work, the ARCH training programme includes scientific, technical and transferable skills courses that will provide ESRs with a solid scientific culture and with awareness of responsible research and innovation issues. This broad portfolio will enable ESRs to become leading academic, clinic or industrial players in the field. The unique combination of scientific excellence, quality of the educational programme and experience in translating basic research into exploitable results will provide ARCH with the real possibility of positively contributing to the enhancement of European competitiveness in the development of innovative, targeted drugs/treatments for hematological diseases, which currently represent a serious socio-economical problem for the European health care system.
| ? | |
| Academisch Ziekenhuis Groningen | 265 620 € |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | 250 905 € |
| Centre Europeen de Recherche en Biologie et Medecine | 274 802 € |
| Diagenode | 256 320 € |
| 261 500 € | |
| 261 500 € | |
| 243 018 € | |
| Institut Curie | 274 802 € |
| Institut National de la Sante et de la Recherche Medicale | 274 802 € |
| King's College London | 303 173 € |
| MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN e. V. | 252 788 € |
| 263 501 € | |
| Universita Degli Studi DI Roma LA Sapienza | 261 500 € |
| Universita' Degli Studi DI Milano-Bicocca | 261 500 € |
| Veterinaermedizinische Universitaet Wien | 264 207 € |
https://cordis.europa.eu/project/id/813091
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Becton Dickinson Italia S.p.A., Castano Primo, Italie.
Les visualisations de "Becton Dickinson Italia S.p.A. - Financement de l’UE (3 969 936 €) : CHANGEMENTS LIÉS À L’ÂGE DANS L’HÉMATOPOÏÈSE"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
